Daily Courier: Single Column

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

4D Molecular Therapeutics, Inc. - Common Stock (NQ:FDMT)

9.760 -0.310 (-3.08%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 843,238
Open 9.890
Bid (Size) 9.620 (600)
Ask (Size) 11.00 (100)
Prev. Close 10.07
Today's Range 9.670 - 10.09
52wk Range 2.960 - 12.34
Shares Outstanding 42,052,980
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT to Participate in Upcoming Investor Meetings
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
+33.3%
+33.3%
1 Month
+5.7%
+5.7%
3 Month
+28.1%
+28.1%
6 Month
-13.4%
-13.4%
1 Year
+216.9%
+216.9%

More News

Read More
News headline image
4DMT to Participate in Upcoming Investor Conferences
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT Announces New Employment Inducement Grants
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
FDMT Stock Gains Pre-Market After Positive Study Data For Experimental Drug In Eye Disease ↗
Via Stocktwits
News headline image
4DMT Completes Enrollment for 4FRONT-1 Phase 3 Clinical Trial of 4D-150 in Wet AMD
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT Announces New Employment Inducement Grants
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT Provides Company Update and Anticipated Development Milestones for 2026
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT Announces Positive Interim Clinical Data from 4D-710 AEROW Phase 1 Clinical Trial in Cystic Fibrosis Lung Disease
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT Announces New Employment Inducement Grants
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT to Present at the 44th Annual J.P. Morgan Healthcare Conference
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT to Participate in 8th Annual Evercore Healthcare Conference
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT Appoints Kristian Humer as Chief Financial Officer
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT Announces New Employment Inducement Grants
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT Reports Third Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT to Participate in Jefferies 2025 London Healthcare Conference
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
Via Benzinga
News headline image
4DMT Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT Announces Positive Long-Term Data from Phase 1/2 PRISM Clinical Trial in Wet AMD Supporting 4D-150’s Potential as a Backbone Therapy with Consistent and Durable Benefit over Multiple Years
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT Announces Exclusive License Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of 4D-150 in Asia-Pacific
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
Beyond The Numbers: 4 Analysts Discuss 4D Molecular Therapeutics Stock ↗
Via Benzinga
News headline image
4DMT Announces New Employment Inducement Grants
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT to Participate in Chardan's 9th Annual Genetic Medicines Conference
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
4DMT Advances 4D-710 to Phase 2 with Additional Funding and Support from the Cystic Fibrosis Foundation
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
Via Benzinga

Frequently Asked Questions

Is 4D Molecular Therapeutics, Inc. - Common Stock publicly traded?
Yes, 4D Molecular Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does 4D Molecular Therapeutics, Inc. - Common Stock trade on?
4D Molecular Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for 4D Molecular Therapeutics, Inc. - Common Stock?
The ticker symbol for 4D Molecular Therapeutics, Inc. - Common Stock is FDMT on the Nasdaq Stock Market
What is the current price of 4D Molecular Therapeutics, Inc. - Common Stock?
The current price of 4D Molecular Therapeutics, Inc. - Common Stock is 9.760
When was 4D Molecular Therapeutics, Inc. - Common Stock last traded?
The last trade of 4D Molecular Therapeutics, Inc. - Common Stock was at 04/21/26 04:00 PM ET
What is the market capitalization of 4D Molecular Therapeutics, Inc. - Common Stock?
The market capitalization of 4D Molecular Therapeutics, Inc. - Common Stock is 410.44M
How many shares of 4D Molecular Therapeutics, Inc. - Common Stock are outstanding?
4D Molecular Therapeutics, Inc. - Common Stock has 410M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

© Copyright 2015, Daily Courier, Kelowna, BC. Powered by BLOX Content Management System from TownNews.com.